Editas Medicine, Inc. (LON:0IFK)
2.610
+0.011 (0.42%)
At close: Aug 5, 2025
Six Flags Entertainment Revenue
Editas Medicine had revenue of $4.66M USD in the quarter ending March 31, 2025, with 310.40% growth. This brings the company's revenue in the last twelve months to $35.84M, down -48.37% year-over-year. In the year 2024, Editas Medicine had annual revenue of $32.31M, down -58.64%.
Revenue (ttm)
$35.84M
Revenue Growth
-48.37%
P/S Ratio
5.90
Revenue / Employee
$145.68K
Employees
246
Market Cap
163.64M
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Editas Medicine News
- 4 weeks ago - Startups Pivot From SEO to AI Visibility(EDIT) - GuruFocus
- 5 weeks ago - Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? - The Motley Fool
- 7 weeks ago - Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
- 7 weeks ago - Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 2 months ago - Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
- 2 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 2 months ago - Editas Medicine: A Cautionary Tale for Investors - The Motley Fool
- 3 months ago - Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha